IL-1 signaling in obesity-induced hepatic lipogenesis and steatosis.

Non-alcoholic fatty liver disease is prevalent in human obesity and type 2 diabetes, and is characterized by increases in both hepatic triglyceride accumulation (denoted as steatosis) and expression of pro-inflammatory cytokines such as IL-1β. We report here that the development of hepatic steatosis...

Full description

Bibliographic Details
Main Authors: Kimberly A Negrin, Rachel J Roth Flach, Marina T DiStefano, Anouch Matevossian, Randall H Friedline, DaeYoung Jung, Jason K Kim, Michael P Czech
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4162604?pdf=render
_version_ 1819259579940208640
author Kimberly A Negrin
Rachel J Roth Flach
Marina T DiStefano
Anouch Matevossian
Randall H Friedline
DaeYoung Jung
Jason K Kim
Michael P Czech
author_facet Kimberly A Negrin
Rachel J Roth Flach
Marina T DiStefano
Anouch Matevossian
Randall H Friedline
DaeYoung Jung
Jason K Kim
Michael P Czech
author_sort Kimberly A Negrin
collection DOAJ
description Non-alcoholic fatty liver disease is prevalent in human obesity and type 2 diabetes, and is characterized by increases in both hepatic triglyceride accumulation (denoted as steatosis) and expression of pro-inflammatory cytokines such as IL-1β. We report here that the development of hepatic steatosis requires IL-1 signaling, which upregulates Fatty acid synthase to promote hepatic lipogenesis. Using clodronate liposomes to selectively deplete liver Kupffer cells in ob/ob mice, we observed remarkable amelioration of obesity-induced hepatic steatosis and reductions in liver weight, triglyceride content and lipogenic enzyme expressions. Similar results were obtained with diet-induced obese mice, although visceral adipose tissue macrophage depletion also occurred in response to clodronate liposomes in this model. There were no differences in the food intake, whole body metabolic parameters, serum β-hydroxybutyrate levels or lipid profiles due to clodronate-treatment, but hepatic cytokine gene expressions including IL-1β were decreased. Conversely, treatment of primary mouse hepatocytes with IL-1β significantly increased triglyceride accumulation and Fatty acid synthase expression. Furthermore, the administration of IL-1 receptor antagonist to obese mice markedly reduced obesity-induced steatosis and hepatic lipogenic gene expression. Collectively, our findings suggest that IL-1β signaling upregulates hepatic lipogenesis in obesity, and is essential for the induction of pathogenic hepatic steatosis in obese mice.
first_indexed 2024-12-23T19:12:16Z
format Article
id doaj.art-66320ee6e11440dabb45ca7cea33b6bf
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-23T19:12:16Z
publishDate 2014-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-66320ee6e11440dabb45ca7cea33b6bf2022-12-21T17:34:25ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0199e10726510.1371/journal.pone.0107265IL-1 signaling in obesity-induced hepatic lipogenesis and steatosis.Kimberly A NegrinRachel J Roth FlachMarina T DiStefanoAnouch MatevossianRandall H FriedlineDaeYoung JungJason K KimMichael P CzechNon-alcoholic fatty liver disease is prevalent in human obesity and type 2 diabetes, and is characterized by increases in both hepatic triglyceride accumulation (denoted as steatosis) and expression of pro-inflammatory cytokines such as IL-1β. We report here that the development of hepatic steatosis requires IL-1 signaling, which upregulates Fatty acid synthase to promote hepatic lipogenesis. Using clodronate liposomes to selectively deplete liver Kupffer cells in ob/ob mice, we observed remarkable amelioration of obesity-induced hepatic steatosis and reductions in liver weight, triglyceride content and lipogenic enzyme expressions. Similar results were obtained with diet-induced obese mice, although visceral adipose tissue macrophage depletion also occurred in response to clodronate liposomes in this model. There were no differences in the food intake, whole body metabolic parameters, serum β-hydroxybutyrate levels or lipid profiles due to clodronate-treatment, but hepatic cytokine gene expressions including IL-1β were decreased. Conversely, treatment of primary mouse hepatocytes with IL-1β significantly increased triglyceride accumulation and Fatty acid synthase expression. Furthermore, the administration of IL-1 receptor antagonist to obese mice markedly reduced obesity-induced steatosis and hepatic lipogenic gene expression. Collectively, our findings suggest that IL-1β signaling upregulates hepatic lipogenesis in obesity, and is essential for the induction of pathogenic hepatic steatosis in obese mice.http://europepmc.org/articles/PMC4162604?pdf=render
spellingShingle Kimberly A Negrin
Rachel J Roth Flach
Marina T DiStefano
Anouch Matevossian
Randall H Friedline
DaeYoung Jung
Jason K Kim
Michael P Czech
IL-1 signaling in obesity-induced hepatic lipogenesis and steatosis.
PLoS ONE
title IL-1 signaling in obesity-induced hepatic lipogenesis and steatosis.
title_full IL-1 signaling in obesity-induced hepatic lipogenesis and steatosis.
title_fullStr IL-1 signaling in obesity-induced hepatic lipogenesis and steatosis.
title_full_unstemmed IL-1 signaling in obesity-induced hepatic lipogenesis and steatosis.
title_short IL-1 signaling in obesity-induced hepatic lipogenesis and steatosis.
title_sort il 1 signaling in obesity induced hepatic lipogenesis and steatosis
url http://europepmc.org/articles/PMC4162604?pdf=render
work_keys_str_mv AT kimberlyanegrin il1signalinginobesityinducedhepaticlipogenesisandsteatosis
AT racheljrothflach il1signalinginobesityinducedhepaticlipogenesisandsteatosis
AT marinatdistefano il1signalinginobesityinducedhepaticlipogenesisandsteatosis
AT anouchmatevossian il1signalinginobesityinducedhepaticlipogenesisandsteatosis
AT randallhfriedline il1signalinginobesityinducedhepaticlipogenesisandsteatosis
AT daeyoungjung il1signalinginobesityinducedhepaticlipogenesisandsteatosis
AT jasonkkim il1signalinginobesityinducedhepaticlipogenesisandsteatosis
AT michaelpczech il1signalinginobesityinducedhepaticlipogenesisandsteatosis